Risk factors for pulmonary hypertension at the predialysis stage of chronic kidney disease


Cite item

Abstract

Aim. To investigate the incidence and risk factors of pulmonary hypertension (PH) in patients with chronic kidney disease (CKD). Subjects and methods. 86 patients (53% men, 47% women; mean age, 45±13 years) with nondiabetic CKD were examined. According to the magnitude of glomerular filtration rate (GFR) decrease, all the patients were divided into 3 groups: 1) 33 patients with a GFR of 89—45 ml/min; 2) 33 with a GFR of 44—15 ml/min; 3) 20 with a GFR of <15 ml/min who were treated with hemodialysis. A control group consisted of 20 individuals with preserved kidney function (a GFR of >90 ml/min). Physical examination and transthoracic echocardiography were performed in all the patients. The serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNT) and cystatin C were determined. Results. PH was detected in 21 (24.4%) of the 86 patients with CKD. As CKD progressed, its prevalence in Groups 1, 2, and 3 increased, amounting to 18.2, 24.2, and 35%, respectively. The most predictably significant risk factors for PH were hypertension (ρ=0.35; р=0.001) and kidney dysfunction (creatinine (ρ=0.23; р=0.02). Elevated pulmonary artery systolic pressure (PASP) correlated with right ventricular (RV) dimension index (ρ=0.45; р<0.0001), right atrial volume index (ρ=0.3; р=0.02), left atrial volume index (ρ=0.3; р=0.009), and left ventricular mass index (ρ=0.35; р=0.03). In all the patients with CKD in the presence of PH, the NT-proBNP level was significantly higher than in its absence: 37.43 (5.83; 59.84) and 8.54 (5.1; 20.43) fmol/ml, respectively (р=0.01). Positive correlations were found between the level of cystatin C and the presence of PH (ρ=0.32; р=0.003). Analysis of the ROC curve (AUC=0.718; р=0.03) in the predialysis-stage CKD groups (n=66) revealed that the cystatin C level of > 1045 ng/ml with a sensitivity of 71% and a specificity of 60% suggested that PH was present. Multivariate analysis showed that the factors correlating with the presence of PH were NT-proBNP (β=0.34; р=0.008) and RV dimension index (β=0.3; р=0.002). Conclusion. EchoCG reveals PH in almost 25% of the patients with CKD, which occurs at its predialysis stage. Elevated PASP is associated with myocardial structural changes. Traditional risk factors (hypertension) and diminished kidney function affect the development of PH.

References

  1. Yigla M, Nakhoul F, Sabag, A, Tov N, Gorevich B, Abassi Z, Reisner SA. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003;123:1577-1582. doi: 10.1378/chest.123.5.1577.
  2. Galie N, Hoeper MM, Humbert M, Torbicki А, Vachiery J-L, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez МА, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian (Chairperson) A, Auricchio A, Bax J, Ceconi С, Dean V, Filippatos G, Funck-Brentano Christian, Hobbs R, Kearney P, McDonagh Th, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann М, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L., Kitsiou AN, Lang I., Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MTS, Vonk-Noordegraaf A, Zamorano JL. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30:2493-2537. doi: 10.1093/eurheartj/ehp297.
  3. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Sanchez MAG, Kumar RK, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34-D41. doi: 10.1016/j.jacc.2013.10.029.
  4. Bozbas SS, Akcay S, Altin C, Bozbas H, Karacaglar E, Kanyilmaz S, Sayin B, Muderrisoglu H, Haberal M. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplantation Proceedings. 2009;41:2753-2756. doi: 10.1016/j.transproceed.2009.07.049.
  5. Etemadi J, Zolfaghari H, Firoozi R, Ardalan MR, Toufan M, Shoja MM, Ghabili K. Unexplained pulmonary hypertension in peritoneal dialysis and hemodialysis patients. Revista Portuguesa de Pneumologia. 2012;18:10-14. doi: 10.1016/j.rppneu.2011.07.002.
  6. Unal A, Sipahioglu M, Oguz F, Kaya M, Kucuk H, Tokgoz B, Buyukoglan H, Oymak O, Utas C. Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Peritоneal Dials Intern. 2009;29:191-198.
  7. Casas-Aparicio G, Castillo-Martínez L, Orea-Tejeda A, Abasta-Jiménez M, Keirns-Davies C, Rebollar-González V. The effect of successful kidney transplantation on ventricular dysfunction and pulmonary hypertension. Transplant Proceed. 2010;42:3524-3528. doi: 10.1016/j.transproceed.2010.06.026.
  8. Fabbian F, Cantelli S, Molino C, Pala M, Longhini C, Portaluppi F. Pulmonary hypertension in dialysis patients: a cross-sectional Italian study. Int J Nephrol. 2011;2011:ID 283475,4. doi: 10.4061/2011/.
  9. Kumbar L, Fein PA, Rafiq MA, Borawski C, Chattopadhyay J, Avram MM. Pulmonary hypertension in peritoneal dialysis patients. Advanc Peritoneal Dial. 2007;23:127-131.
  10. Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012;27:3908-3914. doi: 10.1093/ndt/gfr661.
  11. Kiykim AA, Horoz M, Ozcan T, Yildiz I, Sari S, Genctoy G. Pulmonary hypertension in hemodialysis patients without arteriovenous fistula: the effect of dialyzer composition. Renal Fail. 2010;32:1148-1152. doi: 10.3109/0886022X.2010.516854.
  12. Бородулина E.O., Карпунин С.А., Шутов А.М. Легочная гипертензия у больных на гемодиализе. Клиническая нефрология. 2015;1:19-22.
  13. Yigla M, Fruchter O, Aharonson D, Yanay N, Reisner SA, Lewin M, Nakhoul F. Pulmonary hypertension is an independent predictor of mortality in hemodialysis patients. Kidney Int. 2009;75:969-975. doi: 10.1038/ki.2009.10.
  14. Issa N, Krowka MJ, Griffin MD, Hickson LJ, Stegall MD, Cosio FG. Pulmonary hypertension is associated with reduced patient survival after kidney transplantation. Transplantation. 2008;86: 1384-1388. doi: 10.1097/TP.0b013e318188d640.
  15. Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol. 2008;28:990-997. doi: 10.1159/000146076.
  16. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, Dinc G. Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007;74:503-510. doi: 10.1159/000102953).
  17. Li Z, Liang X, Liu S, Ye Z, Chen Y, Wang W, li R, Xu L, Feng Z, Shi W. Pulmonary hypertension: epidemiology in different CKD stages and its association with cardiovascular morbidity. PLOS ONE. 2014;9(12):e114392. doi: 10.1371/journal.pone.0114392.
  18. Yang QM, Bao XR. Pulmonary hypertension in patients with stage 1—3 chronic kidney disease. Genet Mol Res. 2014;13(3):5695-5703. doi: 10.4238/2014.July.25.25.
  19. Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, Lindholm B, Parati G, Sicari R, Gargani L, Mallamaci F, London G, Zoccali C. Pulmonary Hypertension in CKD. Am J Kidney Dis. 2013;61(4):612-622. doi: 10.1053/j.ajkd.2012.07.029.
  20. Kawar B, Ellam T, Jackson C, Kiely D. Pulmonary Hypertension in Renal Disease: Epidemiology, Potential Mechanisms and Implications. Am J Nephrol. 2013;37:281-290. doi: 10.1159/000348804.
  21. Zoccali C. Pulmonary hypertension in dialysis patients: a prevalent, risky but still uncharacterized disorder. Nephrol Dial Transplant. 2012;27:3674-3677. doi: 10.1093/ndt/gfs425.
  22. Чазова И.Е., Авдеев С.Н., Царева Н.А., Волков А.В., Мартынюк Т.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив. 2014;9:4-23.
  23. Fenster BE, Lasalvia L, Schroeder JD, Smyser J, Silveira LJ, Buckner JK, Brown KK. Cystatin C: A potential biomarker for pulmonary arterial hypertension. Respirology. 2014;19:583-589. doi: 10.1111/resp.12259.
  24. Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, Costa SP. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010;25:3090-3096. doi: 10.1093/ndt/gfq141.

Copyright (c) 2016 Rudenko T.E., Vasilyeva M.P., Solomakhina N.I., Kutyrina I.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies